Katz Family Division of Nephrology and Hypertension, University of Miami Miller School of Medicine, Miami, FL.
Department of Medicine, Section of Nephrology, University of Chicago, Chicago, IL.
Adv Kidney Dis Health. 2023 Jul;30(4):368-377. doi: 10.1053/j.akdh.2023.07.004.
Chronic kidney disease among liver transplant recipients is common and associated with an increased mortality risk. Several risk factors and causes for the development of chronic kidney disease have been identified. They can be divided into perioperative factors, such as unresolved acute kidney injury; donor-related factors, such as the use of extended criteria liver allografts; and recipient-related factors, such as the use of calcineurin inhibitors and the presence of metabolic syndrome, diabetes, and obesity. There is a bimodal progression, more prominent during the initial post-transplant months, followed by a gradual but progressive decline over the subsequent years. Management strategies to prevent and treat chronic kidney disease in the general population can be reasonably applied to the liver transplant population and include addressing comorbidities such as hypertension and diabetes. Strategies to minimize or withdraw calcineurin inhibitors from the immunosuppressive regimen can slow progression of kidney dysfunction. Patients with advanced chronic kidney disease should be considered for kidney transplantation due to its survival advantage. Allocation policy in the United States confers safety-net allocation priority for liver transplant recipients who develop advanced chronic kidney disease within the first year of liver transplantation.
肝移植受者的慢性肾脏病很常见,并且与死亡率增加相关。已经确定了几种导致慢性肾脏病发展的风险因素和病因。这些因素可分为围手术期因素,如未解决的急性肾损伤;供体相关因素,如使用扩展标准的肝移植物;以及受体相关因素,如钙调神经磷酸酶抑制剂的使用和代谢综合征、糖尿病和肥胖的存在。其进展呈双峰模式,在移植后最初几个月更为明显,随后在随后的几年中逐渐但逐渐恶化。预防和治疗普通人群慢性肾脏病的管理策略可以合理地应用于肝移植人群,包括解决高血压和糖尿病等合并症。尽量减少或停止免疫抑制方案中钙调神经磷酸酶抑制剂的使用策略可以减缓肾功能障碍的进展。由于具有生存优势,应考虑将晚期慢性肾脏病患者进行肾移植。美国的分配政策赋予了在肝移植后 1 年内发生晚期慢性肾脏病的肝移植受者安全网分配优先级。